Clinical Trial Detail

NCT ID NCT01681433
Title OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone
Recruitment Terminated
Gender male
Phase Phase II
Variant Requirements No
Sponsors Costantine Albany
Indications

prostate adenocarcinoma

Therapies

Prednisone

Abiraterone

Apatorsen

Age Groups: adult

No variant requirements are available.